OPDIVO for Metastatic NSCLC
~ Dr. Kumudini Rao
Immunotherapy is predicting a revolution in cancer care. Lung cancer has recently emerged as an exciting new target of immune-based therapies. In March 2015, the FDA approved the immunotherapy nivolumab (Opdivo®) for the treatment of advanced (metastatic) squamous NSCLC that has failed chemotherapy. This approval was based on results of a phase III trial which showed that patients receiving nivolumab lived, on average, 3.2 months longer than patients receiving standard chemotherapy. This translates into a 40% reduced risk of death.
Lung cancer is the most common cause of cancer mortality globally, representing 13% of all cancer diagnoses each year and nearly 1 in 5 cancer-related deaths. The majority of lung cancer patients are diagnosed with advanced disease. We anticipate that immunotherapy will change these statistics.
We at Andrews and Patel Associates are very experienced with these treatments for our patients with metastatic melanoma and looking forward to using these treatments in patients with metastatic squamous cell carcinoma of the lung.